Investigational drug · Phase 2
TL117
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Head and Neck Squamous Cell Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "TL117"
First trial start
2021
May 26, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TL117", any sponsor or status.
Conditions studied
As listed on its trial records.
- Head and Neck Squamous Cell Carcinoma
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "TL117" as an intervention, largest first.
- Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaCompleted
Suzhou Junde Biotechnology Co., LtdIndustry
NCT04843098 · 13 participants · Start May 26, 2021 · Primary completion Nov 20, 2024
Drug: TL117; Paclitaxel · For: Head and Neck Squamous Cell Carcinoma
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Endohedral nickel and palladium atoms in metal clusters: analogy to endohedral noble gas atoms in fullerenes in polyhedra with five-fold symmetry.
King RB · Dalton Trans 2004
- A(15)Tl(27) (A = Rb, Cs): A Structural Type Containing Both Isolated Clusters and Condensed Layers Based on the Tl(11) Fragment. Syntheses, Structure, Properties, and Band Structure.
Dong ZC, Corbett JD · Inorg Chem 1996
Also in development for Head and Neck Squamous Cell Carcinoma
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.